1. Home
  2. NTLA vs ELME Comparison

NTLA vs ELME Comparison

Compare NTLA & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • ELME
  • Stock Information
  • Founded
  • NTLA 2014
  • ELME 1960
  • Country
  • NTLA United States
  • ELME United States
  • Employees
  • NTLA N/A
  • ELME N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ELME Real Estate Investment Trusts
  • Sector
  • NTLA Health Care
  • ELME Real Estate
  • Exchange
  • NTLA Nasdaq
  • ELME Nasdaq
  • Market Cap
  • NTLA 1.2B
  • ELME 1.4B
  • IPO Year
  • NTLA 2016
  • ELME N/A
  • Fundamental
  • Price
  • NTLA $13.60
  • ELME $15.94
  • Analyst Decision
  • NTLA Buy
  • ELME Hold
  • Analyst Count
  • NTLA 19
  • ELME 5
  • Target Price
  • NTLA $35.11
  • ELME $18.25
  • AVG Volume (30 Days)
  • NTLA 4.7M
  • ELME 642.1K
  • Earning Date
  • NTLA 08-07-2025
  • ELME 08-05-2025
  • Dividend Yield
  • NTLA N/A
  • ELME 4.53%
  • EPS Growth
  • NTLA N/A
  • ELME N/A
  • EPS
  • NTLA N/A
  • ELME N/A
  • Revenue
  • NTLA $45,569,000.00
  • ELME $243,915,000.00
  • Revenue This Year
  • NTLA N/A
  • ELME $4.84
  • Revenue Next Year
  • NTLA N/A
  • ELME $0.80
  • P/E Ratio
  • NTLA N/A
  • ELME N/A
  • Revenue Growth
  • NTLA N/A
  • ELME 5.31
  • 52 Week Low
  • NTLA $5.90
  • ELME $13.95
  • 52 Week High
  • NTLA $27.42
  • ELME $18.49
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 65.69
  • ELME 44.03
  • Support Level
  • NTLA $12.48
  • ELME $16.04
  • Resistance Level
  • NTLA $14.61
  • ELME $16.35
  • Average True Range (ATR)
  • NTLA 0.90
  • ELME 0.27
  • MACD
  • NTLA 0.13
  • ELME -0.04
  • Stochastic Oscillator
  • NTLA 76.33
  • ELME 19.48

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.

Share on Social Networks: